April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends affordable medicines to millions of Americans, saving the U.S. healthcare system billions every year. But new tariffs announced by President Donald Trump in 2025 could shake things up.
With a 27% tax on Indian goods already in place and a possible 25% tariff on medicines looming, Indian drug companies face tough times. This blog explains what these tariffs mean for India’s generic drugs, active ingredients (APIs), and biologics like biosimilars, focusing on the biggest players sending medicines to the U.S.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
